national center for hiv/aids, viral hepatitis, std, and tb prevention
DESCRIPTION
HIV testing among transgender persons funded by the Centers for Disease Control and Prevention in the United States, Puerto Rico, and U.S. Virgin Islands, 2008-2009 . Oral Poster Discussion : The Global Picture: Transgender Health and Rights. - PowerPoint PPT PresentationTRANSCRIPT
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB PreventionDivision of HIV/AIDS Prevention
HIV testing among transgender persons funded by the Centers for Disease Control and Prevention in
the United States, Puerto Rico, and U.S. Virgin Islands, 2008-2009
Nancy Habarta, Guoshen Wang, and Mesfin S. Mulatu
July 26, 2012
Oral Poster Discussion : The Global Picture: Transgender Health and Rights
Key Findings Transgender (TG) testing events represent a small percentage of
CDC-funded testing events, but have the highest HIV positivity by gender identity
Majority of TG testing events (52%) conducted in non-healthcare facilities
Nearly all (93%) TG testing events followed up with receipt of HIV test results
Key Findings: Among TG testing events Gender
• 83% TG-MTF • 17% TG-FTM
Race/Ethnicity• Blacks (31%) and Hispanics (28%)
accounted for majority
HIV positivity• TG-MTF (2.9%) vs. TG-FTM (1.0%)• Blacks (4.6%) and Hispanics
(2.6%)
Risk behaviors• TG-MTF were more likely than
TG-FTM to report the majority • of risk behaviors
Conclusions TG testing events represent the smallest percentage of overall
testing events but the highest percentage of HIV-positivity, highlighting the need to continue monitoring the epidemic and expanding prevention services for this special population.
HIV testing and positivity among TG varied by race, ethnicity, test facility, and TG identity. HIV prevention services need to be responsive to needs and characteristics of this population
Further improvements in surveillance and prevention data systems is critical to monitor our progress towards achieving our national goal of reducing HIV-related health disparities
For more information please contact Centers for Disease Control and Prevention
1600 Clifton Road NE, Atlanta, GA 30333Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348E-mail: [email protected] Web: http://www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB PreventionDivision of HIV/AIDS Prevention
Nancy Habarta, MPHBehavioral Scientist
Division of HIV/AIDS PreventionNational Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention
Centers for Disease Control and Prevention1600 Clifton Road NE, MS E-49
Atlanta, GA 30333Phone: (404) 639-2034
E-mail: [email protected]